| Document Date: 2013-07-31 09:22:56
Open Document File Size: 2,70 MBShare Result on Facebook
Company N01BB52 C05AA61 J01RA R02AA R02AA20 A01AB14 A01AE11 Pharmaceutical / Reckitt Benckiser / CANA Pharmaceutical Laboratories / 3M ESPE AG / AstraZeneca / / Country Greece / / Facility VI INN / / IndustryTerm pharmaceutical formulation / generic product / treatment of inflammatory diseases / medicinal product / particular product / pharmaceutical formulations / antiarrythmic medicinal product / mg/ml products / medicinal products / / MedicalCondition Sore throat / gingivitis / anal eczema / severe sore throat / dental plaque / stomatitis / pain / throat infections / pains / laryngitis / urinary tract infections / tonsillitis / inflammatory diseases / proctitis / pharyngitis / / MedicalTreatment catheterization / skin surgery / / Movie Male and female / / Organization European Union / / Person Cathejell Lidocaine / / Position EXECUTIVE / CONTENTS I. Executive / / Product Topical / EMLA / epinephrine / Lidocaine / Lidocaine hydrochloride / fluocinonide / / ProvinceOrState Delaware / /
SocialTag |
Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Cathejell Lidocaine, Dynexan, EMLA, Jelliproct, Orofar, Strepsil Plus, Xylestesin-A, Xylo